Healthcare - Press Releases

DES MOINES, Iowa, March 17, 2025 /PRNewswire/ -- Biospace.com, the leading life science news and careers site, is celebrating its 30th anniversary, marking three decades of innovation, industry leadership and unshakable commitment to championing the biopharma community.

Championing Sleep Wellness through Innovation and Education

Bioretec Ltd Press Release 14 March 2025 at 7:00 p.m. EET

Bioretec LtdCompany announcement14 March 2025 at 7:30 p.m. EET

Bioretec LtdCompany announcement14 March 2025 at 7:30 p.m. EET

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ --Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration(FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications.

Sunmed | Your CBD Store Calls for Transparency as Lawmakers Push Undisclosed Amendments

WASHINGTON, March 14, 2025 /PRNewswire/ -- The Human Animal Bond Research Institute (HABRI) and Pet Partners today announced the publication of an important study showing significant reductions in child and parental anxiety and the reduced need for anxiety medication resulting from therapy dog visits in the emergency department. This study, published inJAMA Network was led by Jeffrey A. Kline, MD, Associate Chair of Research at the Department of Emergency Medicine at Wayne State University School of Medicine.

SILVER SPRING, Md., March 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

DENVER, March 14, 2025 /PRNewswire/ -- Espire Dental, a fast-growing, elite, cosmetic and multi-specialty group practice, founded by dentists, is pleased to announce a new partnership with Zollege, which operates Dental Assistant Schools throughout the state which are approved and regulated by the Colorado Department of Higher Education, Private Occupational School Board. This new collaboration expands access to a 12-week, hands-on training Dental Assisting Program that prepares aspiring dental assistants for rewarding careers without the burden of heavy student debt.

GAINESVILLE, Fla, March 14, 2025 /PRNewswire/ -- iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi's capabilities in developing cutting-edge immunotherapies for solid tumors.

SIMI VALLEY, Calif., March 14, 2025 /PRNewswire/ -- Adventist HealthSimi Valley is proud to announce the opening of its newly designed clinic, a major step forward in providing high-quality, accessible healthcare to the community.This new facility combines two former clinics into one streamlined location, increasing efficiency, improving patient flow, and expanding access to primary and specialty care.

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic.

The Series C financing was led by a global strategic investor along with participation from new investors Aphelion Cardeation and Unorthodox Ventures. Existing investors Engage Venture Partners, JWC Venture and Features Capital also participated in the round. Laplace Interventional plans to use the funds raised from this round towards completing their Early Feasibility Study (EFS) and work towards a pivotal study approval.

PERTH, Australia, March 16, 2025 /PRNewswire/ -- ArgentBioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA, a novel anti-inflammatory treatment. The study confirmed CimetrA's strong safety profile and demonstrated faster recovery times in COVID-19 patients.

CANTON, Conn., March 17, 2025 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a manufacturer of custom cranial implants, has announced its financial results for the year ended December 31, 2024.

NORTH CHICAGO, Ill., March 15, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemotherapy.1 Ovarian cancer patients often present with late-stage disease and are historically first treated with platinum-based chemotherapy, which they may become resistant to and require another therapy, such as ELAHERE.2

SIMI VALLEY, California, 15 de marzo de 2025 /PRNewswire-HISPANIC PR WIRE/ -- Adventist Health Simi Valley se enorgullece en anunciar la apertura de su clnica de nuevo diseo, un gran paso adelante para proporcionar atencin mdica accesible y de alta calidad a la comunidad.Esta nueva instalacin combina dos clnicas anteriores en una ubicacin simplificada, lo que aumenta la eficiencia, mejora el flujo de pacientes y ampla el acceso a la atencin primaria y especializada.

HONG KONG, March 16, 2025 /PRNewswire/ --Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy.

Structured Coaching Helps Energy Healers Overcome Industry Challenges and Build Sustainable Practices

NEW YORK, March 15, 2025 /PRNewswire/ --The official brand behind Prime Biome, a product developed under Bioventra's portfolio of advanced formulations, has issued a public advisory regarding unauthorized third-party resellers misrepresenting the product online. Reports indicate that unverified vendors online have been listing non-official versions of Prime Biome across various platforms, leading to confusion among consumers.

A featured presentation will be "Enhance Patient Safety With Privacy-Preserving AI:Multimodal DNN and VLM for Event Detection in Healthcare."

SHELTON, Conn., March 13, 2025 /PRNewswire/ --Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces 2024 year-end financial results and provides a corporate update.

COCONUT GROVE, Fla., March 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has rescheduled the release of its financial results for the full-year ended December 31, 2024, to before market open on March 24, 2025.

RA'ANANA, Israel, March 13, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.